Drug intelligence / Profile preview

loberamisal

Development stage: Phase 3
Lead developer: Neurodawn
Modality: Small Molecules
Administration: Intravenous

Overview

Loberamisal (also known as Y-3) is a small-molecule, dual-acting neuroprotective agent and brain cytoprotectant developed for the treatment of acute ischemic stroke. It acts on multiple key pathological processes of the ischemic cascade by dissociating the post-synaptic density protein 95 (PSD95) and neuronal nitric oxide synthase (nNOS) complex, thereby inhibiting excitotoxicity. Additionally, it targets myeloperoxidase (MPO) and potentiates α2-containing γ-aminobutyric acid type A (GABA-A) receptors. Developed by China Medical System Holdings (CMS) and manufactured by NeuroDawn Pharmaceutical, loberamisal is administered via intravenous infusion. Its New Drug Application (NDA) was accepted by China's National Medical Products Administration (NMPA) in December 2025.

Other names: Loberamisal for Injection

Targets

Postsynaptic density protein 95/neuronal nitric oxide synthase complex (PSD-95/nNOS complex)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)DLG4 (Disks Large Homolog 4)

Beyond the preview

Go deeper on loberamisal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on loberamisal.

Explore the full profile